Articles by Todd Levine
The Syn-Q study: detection of cutaneous phosphorylated alpha-synuclein in Parkinson’s disease progression: a trial protocol
Abstract Background: Parkinson’s disease (PD) is a neurodegenerative condition with progressive phosphorylated alpha-synuclein (P-SYN) deposition. Skin biopsies are a sensitive and specific source of tissue to detect intra-axonal P-SYN in patients with PD. Further, isolated REM sleep behavior disorder (iRBD) is a prodromal condition with a high risk of phenoconversion to PD.
The Syn-sleep trial protocol: detection of cutaneous phosphorylated alpha-synuclein in REM sleep behavior disorder
ABSTRACT Background Idiopathic rapid eye movement sleep behavior disorder (iRBD) is a prodromal neurodegenerative disease of misfolded alpha-synuclein (P-SYN) with a high risk of phenoconversion to a clinically apparent synucleinopathy (including Parkinson’s disease, multiple system atrophy, or dementia with Lewy bodies) over 15 years.
Cutaneous Phosphorylated Alpha‐Synuclein in Lewy Body Dementia
1 Introduction The neurodegenerative diseases collectively known as “synucleinopathies” include Parkinson's disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), and pure autonomic failure (PAF). Despite overlapping clinical phenotypes, the disorders are considered distinct entities with unique pathological underpinnings, but all are characterized by the deposition of phosphorylated alpha-synuclein (P-SYN) within the central and peripheral nervous systems.
Syn-One Test Detects Early Parkinson Risk in REM Sleep Disorder, With Todd Levine, MD
At SLEEP 2025, Todd Levine, MD, presented on a recent study that showed the Syn-One Test detected phosphorylated alpha-synuclein (P-SYN) in 75% cases of REM sleep behavior disorder (RBD).1,2 HCPLive spoke with Levine about this study, and in the first half of the interview, he discussed the significance of these findings, how the Syn-One Test works, and how skin biopsy tests may change the diagnostic workflow for patients presenting with suspected idiopathic RBD (iRBD).
Skin Test Detects Neurodegeneration Risk in 75% of iRBD Cases, With Todd Levine, MD
In a study presented at SLEEP 2025, the 39th annual meeting of the Associated Professional Sleep Societies, on Monday, June 9 in Seattle, 75% cases of REM sleep behavior disorder (RBD) at the initial visit had detected phosphorylated alpha-synuclein (P-SYN).1,2 At the meeting, HCPLive spoke with investigator Todd Levine, from CND Life Sciences, on the significance of these findings, how the Syn-One Test works, and how skin biopsy-based tests may change the diagnostic workflow for patients...
A simple blood test could change how we detect Alzheimer’s - years before memory loss begins
If you’ve ever watched a loved one slowly lose their memory, their sense of self, their ability to recognize family or hold a conversation — you know how devastating Alzheimer’s disease can be. It’s something we neurologists have been fighting for decades. And while we’ve made progress, one of the biggest hurdles has always been early detection. But that may finally be changing.
A blood test could change how we detect Alzheimer’s years before memory loss begins
Todd Levine, MD Submitted photo/Bruce Racine By Todd Levine, MD | HonorHealth Neurology If you’ve ever watched a loved one slowly lose their memory, their sense of self, their ability to recognize family or hold a conversation — you know how devastating Alzheimer’s disease can be. It’s something we neurologists have been fighting for decades. And while we’ve made progress, one of the biggest hurdles has always been early detection. But that may finally be changing.
New blood test could help spot Alzheimer’s risk early
If you’ve ever watched a loved one slowly lose their memory, their sense of self, their ability to recognize family or hold a conversation — you know how devastating Alzheimer’s disease can be. It’s something we neurologists have been fighting for decades. And while we’ve made progress, one of the biggest hurdles has always been early detection. But that may finally be changing.
A 40‐week phase 2B randomized, multicenter, double‐blind, placebo‐controlled study evaluating the safety and efficacy of memantine in amyotrophic lateral sclerosis
ALS amyotrophic lateral sclerosis ALS-CBS ALS Cognitive Behavioral Screen ALSFRS-R Revised Amyotrophic Lateral Sclerosis Functional Rating Scale CHIT-1 chitinase 1 CSF cerebrospinal fluid EAAT-2 excitatory amino acid transporter FTD frontotemporal dementia FVC forced vital capacity NfL neurofilament light chain NMDA N-methyl-d-aspartate NO nitric oxide NPI-Q Neuropsychiatric Inventory Questionnaire pNF-H phosphorylated neurofilament heavy chain ROS reactive oxygen species SOD1 superoxide...
Detection of Phosphorylated α-Synuclein in Patients With Synucleinopathies-Reply
Detection of Phosphorylated α-Synuclein in Patients With Synucleinopathies—Reply Skin Biopsy Detection of Phosphorylated α-Synuclein in Patients With Synucleinopathies Christopher H. Gibbons, MD, MMSc; Todd Levine, MD; Charles Adler, MD, PhD; Bailey Bellaire, BS; Ningshan Wang, PhD; Jade Stohl, BA; Pinky Agarwal, MD; Georgina M. Aldridge, MD, PhD; Alexandru Barboi, MD; Virgilio G. H. Evidente, MD; Douglas Galasko, MD; Michael D.
Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study
For CIDP01, sample size calculation used a one-sided 5.0% t-test for comparison of rozanolixizumab and placebo, and an anticipated effect size index of 0.93. Based on this, a sample size of 15 in each group was required to provide 80% power to detect a statistically significant difference. If the effect size index was medium (0.52), the power decreased to 40%.
Scottsdale doctor helps create skin test to help detect diseases like Parkinson’s or dementia
SCOTTSDALE, AZ (3TV/CBS 5) — Valley doctors are making national headlines for creating a first-of-its-kind test. They say it helps detect diseases like Parkinson’s disease and dementia. Their test uses a skin sample to diagnose the diseases quicker and more accurately. The test is being used in doctors’ offices across the Valley and the country. It’s a simple 15-minute procedure where a doctor will take a small skin sample and then send those results to the biotech company in Scottsdale.
Skin Biopsy Detection of Phosphorylated α-Synuclein in Patients With Synucleinopathies
Key Points Question Can skin biopsy detect phosphorylated α-synuclein in individuals with synucleinopathies such as Parkinson disease (PD), multiple system atrophy (MSA), dementia with Lewy bodies (DLB), and pure autonomic failure (PAF)?
Researchers developing finger prick blood test to detect Alzheimer’s
PHOENIX (3TV/CBS 5) -- Arizona has the fastest growth rate for Alzheimer’s in the country. Now, there’s new hope on the horizon for getting answers earlier with a simple finger prick blood test. Blood tests can help doctors diagnose lots of serious health conditions, from diabetes to HIV and cancer. Alzheimer’s could be next. Dr. Jessica Langbaum hasbeen working in Alzheimer’s research for nearly two decades. “My own grandfather was diagnosed with mild cognitive impairment many years ago,” she said.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Todd
Contact Todd, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack